A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety profile of MGCD265 when administered
in combination with the marketed anticancer drugs erlotinib and docetaxel.